MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Assertio Holdings Revenue 2011-2026 | ASRT
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Assertio Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152 M | 156 M | 111 M | 106 M | 230 M | 312 M | 381 M | 456 M | 343 M | 390 M | 134 M | 90.8 M | 133 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 456 M | 90.8 M | 230 M |
Quarterly Revenue Assertio Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 49.5 M | 29.2 M | 26.5 M | - | 29.2 M | 31.1 M | 32.4 M | - | 35.6 M | 41 M | 42.5 M | - | 34.2 M | 35.1 M | 36.5 M | - | 25.5 M | 25.4 M | 26.8 M | - | 34.6 M | 20.6 M | 20.9 M | - | 55.1 M | 57.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 57.2 M | 20.6 M | 34.5 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
651 K | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.07 | -0.47 % | $ 115 M |  Canada |
 |
DURECT Corporation
DRRX
|
8.55 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Harrow Health
HROW
|
272 M | $ 38.95 | -27.32 % | $ 1.43 B | USA |
 |
Cronos Group
CRON
|
46.7 M | $ 2.62 | -0.57 % | $ 1.36 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
702 K | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
4.53 M | $ 0.55 | -0.97 % | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 4.5 | -7.02 % | $ 63.3 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
25 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.52 | -5.26 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 2.86 | -4.67 % | $ 377 M | USA |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 8.87 | -1.33 % | $ 454 M | USA |
 |
ProPhase Labs
PRPH
|
123 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
83.6 M | $ 0.9 | 0.37 % | $ 21 M | USA |
 |
Evolus
EOLS
|
297 M | $ 4.21 | -1.86 % | $ 261 M | USA |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 5.77 | -3.11 % | $ 2.11 B | Canada |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.38 | -3.17 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
4.25 B | $ 11.38 | -7.97 % | $ 1.58 B | USA |
 |
Sundial Growers
SNDL
|
920 M | $ 1.53 | 0.33 % | $ 3.37 M | Canada |
 |
Pacira BioSciences
PCRX
|
542 M | $ 22.06 | 3.67 % | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 4.67 | -3.51 % | $ 141 M | USA |
 |
SCYNEXIS
SCYX
|
140 M | $ 0.73 | -2.19 % | $ 34.9 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 2.76 | -2.66 % | $ 3.43 M | USA |
 |
TherapeuticsMD
TXMD
|
1.3 M | $ 2.26 | 1.0 % | $ 23.6 M | USA |
 |
Tilray
TLRY
|
627 M | $ 7.37 | -2.97 % | $ 4.55 B | Canada |
 |
Veru
VERU
|
16.9 M | $ 2.54 | -3.05 % | $ 343 M | USA |
 |
Viatris
VTRS
|
15.4 B | $ 15.09 | -3.89 % | $ 18.1 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 0.79 | -2.48 % | $ 3.41 M | USA |